NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

Phase: PHASE2 | Sponsor: M.D. Anderson Cancer Center | Compound: Psilocybin

Status

planned

Institution

M.D. Anderson Cancer Center

Start date

2026-05-04

End date

2031-01-31

Registry ID

NCT07227909

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.